Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Study of Maintenance Lurbinectedin in Combination With Serplulimab for Patients With Extensive-Stage Small Cell Lung Cancer

NCT06497530 is registered in ClinicalTrials.gov with Guangzhou Institute of Respiratory Disease as lead sponsor.

NCT NCT06497530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06497530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Study of Maintenance Lurbinectedin in Combination With Serplulimab for Patients With Extensive-Stage Small Cell Lung Cancer
Lead sponsor
Guangzhou Institute of Respiratory Disease
Phase
Phase 2
Overall status
Recruiting
Start date
December 1, 2024
Completion date
December 31, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small cell lung cancer